1599531-10-8

Basic information

• Product Name: 3-(4-(1H-pyrazol-1-yl)benzyl)-6-(hydroxy(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-8-methylquinolin-2,4-dicarbonitrile
• Synonyms: 3-(4-(1H-pyrazol-1-yl)benzyl)-6-(hydroxy(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-8-methylquinolin-2,4-dicarbonitrile
• CAS NO: 1599531-10-8
• Molecular Weight: 604.594
• Mol File: 1599531-10-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-(4-(1H-pyrazol-1-yl)benzyl)-6-(hydroxy(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-8-methylquinolin-2,4-dicarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-(1H-pyrazol-1-yl)benzyl)-6-(hydroxy(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-8-methylquinolin-2,4-dicarbonitrile(1599531-10-8)
• EPA Substance Registry System: 3-(4-(1H-pyrazol-1-yl)benzyl)-6-(hydroxy(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methyl)-8-methylquinolin-2,4-dicarbonitrile(1599531-10-8)

Safety Data

• Hazardous Substances Data: 1599531-10-8(Hazardous Substances Data)

Upstream product

• 1599529-08-4 3-(4-(1H-pyrazol-1-yl)benzyl)-6-bromo-2,4-dichloro-8-methylquinoline 
• 231291-22-8 6-trifluoromethylnicotinic acid 
• 358780-13-9 6-(trifluoromethyl)nicotinoyl chloride 
• 416852-53-4 N-methoxy-N-methyl-6-(trifluoromethyl)pyridine-3-carboxamide 
• 1599524-55-6 (1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methanone 
• 99662-34-7 4-(1H-pyrazol-1-yl)benzaldehyde 
• 1599528-96-7 5-(4-(1H-pyrazol-1-yl)benzyl)-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 1599528-97-8 2-(4-(1H-pyrazol-1-yl)benzyl)malonic acid 
• 557-21-1 zinc(II) cyanide 
• 1599531-11-9 (3-(4-(1H-pyrazol-1-yl)benzyl)-2,4-dichloro-8-methylquinolin-6-yl)(1-methyl-1H-imidazol-5-yl)(6-(trifluoromethyl)pyridin-3-yl)methanol 

Downstream Products

• 1599531-88-0 C₃₃H₂₃F₃N₈O 
• 1599531-89-1 C₃₃H₂₃F₃N₈O 

Relevant articles and documents

METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.